BM-531 

BM-531 is a dual-acting agent for thromboxane receptor (TXA2) antagonism and thromboxane synthase inhibition. BM-531 exerts anti-aggregatory effects on human citrated platelet-rich plasma (PRP), inhibiting Arachidonic acid (HY-109590A)-induced aggregation with an ED₁₀₀ of 0.125 μM and U-46619 (HY-108566)-induced aggregation with an ED₅₀ of 0.482 μM. BM-531 inhibits high-K⁺-induced contraction of porcine uterine smooth muscle^[1][2][3].

BM-531 (0.0001-10 μM) shows high affinity for TXA2 receptor on human washed platelets with an IC₅₀ of 0.0078 μM (displacing [³H]SQ-29548)^[1].
BM-531 exerts anti-aggregatory effects on human citrated platelet-rich plasma (PRP), inhibiting Arachidonic acid (HY-109590A)-induced aggregation with an ED₁₀₀ of 0.125 μM and U-46619 (HY-108566)-induced aggregation with an ED₅₀ of 0.482 μM^[1].
BM-531 (10 μM, 1 h) inhibits high-K⁺-induced contraction of porcine uterine smooth muscle^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

398.48

C₁₇H₂₆N₄O₅S

284464-46-6

O=S(C1=CC([N+]([O-])=O)=CC=C1NC2CCCCC2)(NC(NC(C)(C)C)=O)=O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Dogné JM, et al. Effects of a novel non-carboxylic thromboxane A2 receptor antagonist (BM-531) derived from torasemide on platelet function. Prostaglandins Leukot Essent Fatty Acids. 2000 May;62(5):311-7.  [Content Brief]

  [2]. Cao J, et al. Thromboxane A2 (TP) receptor in the non-pregnant porcine myometrium and its role in regulation of spontaneous contractile activity. Eur J Pharmacol. 2004 Feb 6;485(1-3):317-27.  [Content Brief]

  [3]. Michaux C, et al. N-tert-butyl-N'-(2-cyclohexylamino-5-nitrobenzenesulfonyl)urea, BM531, a dual-acting agent for thromboxane receptor antagonism and thromboxane synthase inhibition. Acta Crystallogr C. 2002 Oct;58(Pt 10):o621-3.  [Content Brief]